OPKO Health, Inc.
NASDAQ:OPKBiotechnology
+$0.01 today
- Market cap
- $1.25B
- Beta
- 1.49
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.28
Volume 3.06M
Average 2.59M
OPK Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
OPKO Health, Inc.NASDAQ: OPK
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit growth accelerates
Q1 FY2026 gross profit of $26.79M rose 17.7% year over year, ahead of the -33.7% change in trailing-twelve-month gross profit. Sequentially, it fell 40.4% from the prior quarter. Over 3 fiscal years it compounded at -23.7% a year.
Context
- Gross profit amounted to 21.1% of revenue in FY2025, down 22.5 pp from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17.7% holds above the trailing-twelve-month pace of -33.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 128.05M USD
- Year-over-year change
- -58.8%
- 4-year CAGR
- -31.5%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 128.05M | -58.8% |
| FY2024 | 2024-12-31 | 311.03M | -2.2% |
| FY2023 | 2023-12-31 | 318.13M | +10.4% |
| FY2022 | 2022-12-31 | 288.22M | -50.4% |
| FY2021 | 2021-12-31 | 581.52M | — |
Gross Profit vs competitors
How OPK compares with its peers on the latest reported figures
- OPK's LTM Mar 2026 gross profit of $132.08M is the 7th highest of the 11 companies compared; the peer median is $272.6M.
- Its year-over-year change of -33.7% is the 10th highest of 11, against a peer median of +13.1%.
- Gross profit amounts to 22.7% of revenue for OPK, versus a peer median of 62.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.77B | +43.1% | +60.2% | 65.3% | |
| LTM Sep 2026 | $833.7M | +44.9% | +29.2% | 65.2% | |
| LTM Mar 2026 | $580M | -0.3% | +6.6% | 70.0% | |
| LTM Jun 2026 | $328.9M | +8.7% | +14.6% | 42.9% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $283.22M | +122.4% | — | 71.3% |
| LTM Mar 2026 | $261.97M | -7.9% | +37.5% | 77.1% | |
| LTM Mar 2026 | $132.08M | -33.7% | -23.7% | 22.7% | |
| LTM Mar 2026 | $124.02M | +9.3% | -29.1% | 38.7% | |
| FY2025 | $64.44M | +16.9% | +49.7% | 59.7% | |
| LTM Mar 2026 | $39.88M | +18.6% | +22.0% | 58.3% | |
| LTM Mar 2026 | $8.85M | -69.0% | — | 13.7% | |
| Peer median (excluding OPK) | $272.6M | +13.1% | +25.6% | 62.5% | |
Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77B | 1B | 863.5M | 713.14M | 606.88M |
| Cost of Revenue | 1.19B | 715.98M | 545.37M | 402.11M | 478.83M |
| Gross Profit | 581.52M | 288.22M | 318.13M | 311.03M | 128.05M |
| Gross Margin | 32.8% | 28.7% | 36.8% | 43.6% | 21.1% |
| Research & Development | 76.85M | 73.89M | 89.59M | 105.21M | 124.03M |
| Selling, General & Admin | 468.86M | 372.67M | 300.56M | 304.22M | 223M |
| Operating Expenses | 562.77M | 514.47M | 475.15M | 463.1M | 347.04M |
| Depreciation & Amortization | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M |
| EBITDA | 83.57M | (270.81M) | (65.52M) | 135.28M | (41.3M) |
| EBITDA Margin | 4.7% | -27.0% | -7.6% | 19.0% | -6.8% |
| Operating Income | 18.75M | (226.25M) | (157.02M) | (152.07M) | (218.99M) |
| Operating Margin | 1.1% | -22.5% | -18.2% | -21.3% | -36.1% |
| Interest Income | 28K | 1.98M | 3.98M | 8.43M | 14.81M |
| Interest Expense | 18.88M | 12.06M | 13.51M | 47.47M | 108.46M |
| Other Income / Expenses | (33.4M) | (165.65M) | (27.41M) | 141.7M | (22.41M) |
| Income Before Tax | (14.65M) | (391.9M) | (184.43M) | (10.36M) | (241.39M) |
| Pre-Tax Margin | -0.8% | -39.0% | -21.4% | -1.5% | -39.8% |
| Income Tax Expense | 15.49M | (63.5M) | 4.44M | 42.84M | (15.71M) |
| Net Income | (30.14M) | (328.41M) | (188.86M) | (53.22M) | (225.68M) |
| Net Margin | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% |
| EPS (Basic) | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) |
| EPS (Diluted) | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) |
| Weighted Avg Shares | 648.08M | 719.06M | 751.77M | 694.02M | 751.13M |
| Weighted Avg Shares (Diluted) | 648.08M | 719.06M | 751.77M | 694.02M | 751.13M |
OPKO Health, Inc.
NASDAQ:OPK
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.